Evidence map›Paper›PMID 32393844›Full record

ReviewLeukemia2020

Chronic lymphocytic leukemia in 2020: a surfeit of riches?

Sameer A Parikh, Robert Peter Gale, Neil E Kay

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Zanubrutinib: past, present, and future.Blood cancer journal · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sameer A ParikhDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. parikh.sameer@mayo.edu.ORCID http://orcid.org/0000-0002-3221-7314
Robert Peter GaleDepartment of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK.
Neil E KayDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Funding

Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)R01AG058266 · NIA · MAYO CLINIC ROCHESTER · PI SHANAFELT, TAIT D, SLAGER, SUSAN L · 2018 to 2022
$3.2M
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic LeukemiaR01CA193541 · NCI · MAYO CLINIC ROCHESTER · PI KAY, NEIL E, SHANAFELT, TAIT D · 2015 to 2019
$2.9M
Department of HealthNCI NIH HHS R01 CA193541NIA NIH HHS R01 AG058266
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAntineoplastic Combined Chemotherapy ProtocolsHumansLeukemia, Lymphocytic, Chronic, B-CellNeoplasm, ResidualAgammaglobulinaemia Tyrosine KinaseBTK protein, human

Identifiers

PMID32393844
PMCPMC8130839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.